Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.

F Hörbrand; D Rottenkolber; J Fischaleck; J Hasford

doi:10.1055/s-0033-1361111

Publisher Website

Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.

Authors

Hörbrand, F
Rottenkolber, D
Fischaleck, J
Hasford, J

Type

Published Article

Journal

Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))

Publication Date

Nov 01, 2014

Volume

76

Issue

11

Identifiers

DOI: 10.1055/s-0033-1361111

PMID: 24493578

Source

Medline

License

Unknown

Abstract

A more common biosimilar prescription in renal anemia patients suffering from chronic kidney disease provides a noteworthy economic savings potential.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/05/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/24493578

Report this publication

Statistics

Seen <100 times